Pazopanib
Inhibitor of BCR-ABL and SRC tyrosine kinase that is used for treatment of several neoplastic diseases.
At latest update, relevant published data on excretion into breast milk were not found.
Because of high serum protein-binding capacity, excretion into breast milk in significant amount is seemingly unlikely.
If continuation of safely breastfeeding is desired without assuming high risk for potentially severe side-effects, elimination of total burden of drug should be kept. For this to happen, it should be wait for 10 half-lives (T ½).
It means that 13 days should be waited before resuming breastfeeding.
Meanwhile, frequent pump-and-dump is recommended for maintenance of milk production.
Alternatives
We do not have alternatives for Pazopanib.
Very Low Risk
Compatible. Not risky for breastfeeding or infant.
Low Risk
Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.
High Risk
Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.
Very High Risk
Not recommended. Cessation of breastfeeding or alternative.
Synonyms
- Пазопаниба Гидрохлорид
- パゾパニブ塩酸塩
Drug trade names
References
- PDR.net. Pazopanib. Drug Summary. 2014 Full text (link to original source) Full text (in our servers)
- Deng Y, Sychterz C, Suttle AB, Dar MM, Bershas D, Negash K, Qian Y, Chen EP, Gorycki PD, Ho MY. Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013Abstract
- EMEA. Pazopanib. Ficha técnica. 2012 Full text (in our servers)
- Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf J, Jaehde U. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet. 2011Abstract